AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BriaCell Therapeutics Joins MSK's 2025 Therapeutics Accelerator Program
ByAinvest
Thursday, Aug 14, 2025 8:35 pm ET1min read
BriaCell Therapeutics has been selected for Memorial Sloan Kettering Cancer Center's 2025 Therapeutics Accelerator Program to advance Bria-OTS+ immunotherapy development. The collaboration aims to accelerate development and regulatory processes for the cancer treatment. Despite a challenging financial position and mixed technical indicators, recent corporate developments provide potential upside.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT) has been selected for Memorial Sloan Kettering Cancer Center’s (MSK) 2025 Therapeutics Accelerator Program, aiming to accelerate the clinical development of Bria-OTS+, the company’s next-generation personalized off-the-shelf immunotherapy. This collaboration is intended to expedite Bria-OTS+ development for multiple cancer indications, including metastatic breast cancer and prostate cancer.As one of the world’s foremost cancer research and treatment institutions, MSK offers over 135 years of leadership in patient care, education, and discovery. The MSK Therapeutics Accelerator Cohort program provides BriaCell with access to MSK’s expertise and institutional resources, including Good Manufacturing Practice (GMP) manufacturing services, Investigational New Drug (IND) Application preparation and submission, and regulatory strategy support.
“We are honored to work with the scientific and clinical experts at MSK Therapeutics Accelerator,” stated Dr. William V. Williams, BriaCell’s President and CEO. “MSK’s deep expertise in cancer therapy development and state-of-the-art resources make it an ideal partner to accelerate our personalized off-the-shelf immunotherapy platform.”
Eileen Flowers, PhD, Director of Technology Development & Licensing in the Office of Entrepreneurship and Commercialization at MSK, added, “We are excited to welcome BriaCell into the cohort program.”
Dr. Miguel Lopez-Lago, BriaCell’s Chief Scientific Officer, expressed optimism about the potential of Bria-OTS+ to transform cancer care, stating, “Our participation in this cohort program is yet another step towards achieving that vision.”
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company’s latest financial position and technical indicators present challenges, but recent corporate developments, including this collaboration with MSK, offer potential upside.
References:
[1] https://www.biospace.com/press-releases/briacell-selected-for-msks-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer
[2] https://drug-dev.com/briacell-selected-for-msks-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet